Jeffrey W. Albers
CIK 1638474 · CEO AND PRESIDENT · last filed 2026-06-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.73M
Companies
5
Total Filings
112
Lifetime Open-Market Net
-$64.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Director | 0 | $106.16 | $0 | -$1.80M | 13 | 2026-06-25 |
| SYRE | Director | 27,360 | $99.96 | $2.73M | -$257.2K | 6 | 2026-05-29 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 0 | $129.46 | $0 | -$62.43M | 69 | 2025-07-21 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Director | — | $12.01 | — | $0 | 1 | 2023-11-27 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 260 | $11.19 | $2.9K | $0 | 5 | 2022-06-30 |
Recent Filings · Page 2 of 12
112 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-03 | KYMR | Mixed | — | -$245.5K | EDGAR |
| 2025-06-02 | SYRE | Grant (A) | — | $0 | EDGAR |
| 2025-05-29 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$325.4K | EDGAR |
| 2025-05-27 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −5,000 | -$505.7K | EDGAR |
| 2025-03-17 | Blueprint Medicines Corp (BPMC) Delisted | Sell (S) | −5,766 | -$512.0K | EDGAR |
| 2025-03-14 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$388.1K | EDGAR |
| 2025-01-23 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | −5,161 | -$1.30M | EDGAR |
| 2025-01-21 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −5,161 | -$566.6K | EDGAR |
| 2025-01-15 | Blueprint Medicines Corp (BPMC) Delisted | Mixed | — | -$331.1K | EDGAR |
| 2025-01-14 | Blueprint Medicines Corp (BPMC) Delisted | Notice (144) | −5,000 | -$511.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.